Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH). [Phase 3]

View source ↗

Summary

Phase 3 trial updating efficacy and safety of JS002 in patients with heterozygous familial hypercholesterolemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heterozygous Familial Hypercholesterolemia

Drugs mentioned

• JS002

Snippet

Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Conditions: Heterozygous Familial Hypercholesterolemia | Phase 3 | Status: COMPLETED